Patrys Limited (AU:PAB) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrys Limited has bolstered its financial standing by receiving a $1.285 million rebate through the Australian Government’s R&D Tax Incentive scheme. This refund supports the ongoing development of their innovative deoxymab platform, which targets cancer cells and inflammatory diseases. The company’s commitment to advancing these therapies could potentially revolutionize cancer treatment options.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.